After more than 10 years of raising awareness about sarcopenia and its impact on the aging community, our Aging in Motion Coalition has a new presence on the Alliance website.
Shaking the Stigma of NPS in our New Educational Film Series
Behavioral and psychological symptoms of Alzheimer’s and related dementias, also known as neuropsychiatric symptoms (NPS), can be challenging to discuss with patients, caregivers, and even medical professionals.
In an effort to shake the stigma, we've created a film series featuring expert conversations about how to provide support for those experiencing NPS.
While the Alliance celebrates this scientific advancement, we continue to urge the Centers for Medicare & Medicaid Services (CMS) to stop rationing care and immediately retire its excessively restrictive coverage with evidence development (CED) policy.
Hill Briefing Highlights Desire to Access FDA-Approved Alzheimer's Treatments
“Time matters and CMS is wrong to deny or delay for so long..."
On July 11, the Alliance, in partnership with the Caregiver Action Network, hosted an in-person Hill briefing discussing the current state of Medicare coverage for FDA-approved early Alzheimer’s treatments, the inequity impacts on families facing this disease in underserved communities, and the precedent-setting implications of this coverage policy for future breakthrough therapies.
The discussion featured passionate remarks from advocates and caregivers who have been impacted by CMS' coverage with
evidence determination.
Alliance Applauds CMS Proposal to Withdraw Requirement Limiting
Access to PET Scans
On July 17, CMS released a proposed decision memo to remove the national coverage determination (NCD) requiring coverage with evidence development (CED) for Beta Amyloid PET scan use for patients with neurodegenerative diseases.
The proposed decision is the first step in the process to provide Medicare beneficiaries with equitable access to this important imaging tool.
